Results 141 to 150 of about 191,272 (307)
Real‐world treatment patterns and outcomes in accelerated and blast‐phase myeloproliferative neoplasms: Insights from a large multi‐centre cohort analysis in the United Kingdom
British Journal of Haematology, EarlyView.Summary
This UK‐based retrospective analysis describes real‐world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast‐phase (BP, n = 106) ‘Philadelphia‐negative’ myeloproliferative neoplasms (MPN‐AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years.Alexandros Rampotas, Gabriel Naylor‐Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J. Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N. Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C. P. Somervaille, Donal P. McLornan, on behalf of the UK Blood Cancer Research Network MPN Clinical Study Group +35 morewiley +1 more sourceMolecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods
Brain Pathology, EarlyView.This study characterizes the molecular subgroup–specific features of a nationwide Japanese cohort comprising 242 medulloblastomas (MBs). Furthermore, we introduce SEE‐6‐CNA, a simple, cost‐effective, and FFPE‐compatible molecular test that is applicable to routine pathology samples and serves as a surrogate for risk stratification in non‐WNT/non‐SHH ...Kohichi Go, Asako Katsuma, Ema Yoshioka, Tomoko Shofuda, Kohei Fukuoka, Koichi Ichimura, Yuko Matsushita, Yohei Mineharu, Yasuhide Makino, Takeshi Kawauchi, Atsushi Sasaki, Junko Hirato, Takeshi Inoue, Yoshinori Kodama, Masayuki Mano, Daisuke Kanematsu, Noriyuki Kijima, Naoki Kagawa, Dai Keino, Akitake Mukasa, Tomonari Suzuki, Koji Yoshimoto, Daisuke Kuga, Keishi Horiguchi, Shigeru Yamaguchi, Masayuki Kanamori, Kai Yamasaki, Kenichi Ishibashi, Takuya Akai, Masayoshi Yamaoka, Ryuji Ishizaki, Atsufumi Kawamura, Shigeo Ohba, Joji Ishida, Ryo Ando, Junya Fukai, Tomoru Miwa, Masazumi Fujii, Ai Muroi, Kuniaki Saito, Atsuko Harada, Yasuhiko Hayashi, Masahiro Nonaka, Young‐Soo Park, Yusuke Kobayashi, Tadashi Higuchi, Yosuke Miyairi, Kazuhisa Yoshifuji, Noriyoshi Takebe, Soichi Oya, Kosuke Nakajo, Mitsutoshi Nakada, Yoshiteru Nakano, Mizuki Kambara, Koji Adachi, Kazuhiro Tanaka, Hideo Nakamura, Yukihiko Sonoda, Ryuta Saito, Takafumi Wataya, Kazuhiko Kurozumi, Michael D. Taylor, Yoshitaka Narita, Soichiro Shibui, Hajime Arai, Hiroaki Sakamoto, Isao Date, Motoo Nagane, Ryo Nishikawa, Yoshiki Arakawa, Yonehiro Kanemura +70 morewiley +1 more sourceEnhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma
British Journal of Pharmacology, EarlyView.Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez +28 morewiley +1 more sourcecytogenetics
Citation: 'cytogenetics' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.10583 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.openaire +1 more sourceMolecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines
Cancer Science, EarlyView.Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.Kazue Ito, Noriko Ishida, Shin Ito, Norihisa Shindo, Satoshi Souma, Mai Mochizuki, Haruna Fujimori, Keiichi Tamai, Takayuki Imai, Tomoko Yamazaki, Kazunori Yamaguchi, Kento Sasaki, Yuya Miyakura, Shigekazu Murakami, Yuka Unno, Naoki Asano, Yukinori Asada, Jun Yasuda +17 morewiley +1 more sourceDaunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial
Cancer Science, EarlyView.Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT
Daunorubicin dose optimization remains crucial for AML treatment.Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang +15 morewiley +1 more sourceProtocol for deriving proliferating primary fibroblast cultures from Malabar red snapper larvae for cytogenetic analysis. [PDF]
STAR ProtocPurushothaman K, Hazim Bin Mohamed M, Tneo Rwei Qing SD, Vu NT, Liang B, Singh H, Shixiong T, Loo G, Bisa S, Jerry DR, Domingos JA, Vij S. +11 moreeuropepmc +1 more sourceAn Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study
Cancer Science, EarlyView.An immune dysfunction score (IDS) provides independent prognostic information in MDS and CMML, complements current risk models, mirrors disease changes, and reflects underlying immune impairment. IDS may also highlight therapeutic sensitivities, supporting its use as a practical biomarker for risk stratification and clinical follow‐up.Yu‐Hung Wang, Carmelo Gurnari, Valeria Visconte, Arda Durmaz, Luca Guarnera, Wan‐Hsuan Lee, Chi‐Yuan Yao, Andres Jerez, Kristian Gurashi, Kiran Batta, Hsin‐An Hou, Wen‐Chien Chou, Mrinal S. Patnaik, Jaroslaw Maciejewski, Daniel H. Wiseman, Chien‐Chin Lin, Hwei‐Fang Tien +16 morewiley +1 more sourcePrognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification. [PDF]
Blood Cancer JLee WH, Hou HA, Lin CC, Tsai XC, Tien FM, Lo MY, Chang YS, Peng YL, Tseng MH, Kuo YY, Yu SC, Liu MC, Yao CY, Hsu CL, Yuan CT, Yao M, Tien HF, Ko BS, Chou WC. +18 moreeuropepmc +1 more source
